Epsolay is an investigational topical cream that utilizes the Company’s patented technology process to encapsulate benzoyl peroxide 5% within silica-based microcapsules. The New Drug Application (NDA) ...

Epsolay is a topical cream that utilizes a patented technology process to encapsulate benzoyl peroxide 5% within silica-based microcapsules. The Food and Drug Administration (FDA) has approved Epsolay ...

NESS ZIONNA, Israel, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), today announced positive topline data for its open-label, long-term safety study, evaluating ...

The FDA approved benzoyl peroxide 5% cream (Epsolay) for adults with inflammatory lesions of rosacea, Sol-Gel Technologies announced on Monday. Using silica-based microcapsules that create a barrier ...

NESS ZIONA, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded ...

NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology ...

NESS ZIONA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Sol-Gel Technologies announced positive results of a ...

Rosacea is a dermatologic condition affecting the centrofacial region (cheeks, chin, nose, and forehead), resulting in symptoms of facial flushing, swollen bumps on the skin surface, and a burning ...

Sol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined, plus additional royalties ranging from low double-digits to high-teens ...